HealthEquity, Inc. (FRA:2HE)
Germany · Delayed Price · Currency is EUR | Market Cap | 6.86B +2.3% |
| Revenue (ttm) | 1.18B +7.3% |
| Net Income | 205.58M +62.2% |
| EPS | 2.40 +67.9% |
| Shares Out | n/a |
| PE Ratio | 33.38 |
| Forward PE | 18.85 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 81.50 |
| Previous Close | 82.50 |
| Day's Range | 81.50 - 81.50 |
| 52-Week Range | 61.00 - 91.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 27, 2026 |
About HealthEquity
HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. It offers health savings accounts (HAS); investment platform; online-only automated investment advisory services through Advisor, a Web-based tool. The company also provides flexible spending accounts (FSA) for health and dependent care; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. In addition, the company offer... [Read more]
Financial Performance
In fiscal year 2026, HealthEquity's revenue was $1.31 billion, an increase of 9.47% compared to the previous year's $1.20 billion. Earnings were $215.20 million, an increase of 122.54%.
Financial numbers in USD Financial StatementsNews
HealthEquity price target raised to $115 from $110 at Barclays
Barclays raised the firm’s price target on HealthEquity (HQY) to $115 from $110 and keeps an Equal Weight rating on the shares. The company’s historical correlation to interest rates during…
HealthEquity price target raised to $142 from $135 at Deutsche Bank
Deutsche Bank raised the firm’s price target on HealthEquity (HQY) to $142 from $135 and keeps a Buy rating on the shares. The firm updated the company’s model post the…
HealthEquity falls -12.6%
HealthEquity (HQY) is down -12.6%, or -$13.12 to $91.31.
HealthEquity falls -14.1%
HealthEquity (HQY) is down -14.1%, or -$14.68 to $89.74.
HealthEquity Earnings Call Transcript: Q2 2027
Q2 delivered accelerated revenue growth, record profitability, and raised full-year guidance, driven by strong HSA account and asset growth, expanding digital engagement, and operational efficiencies. Marketplace activity and investing adoption reached new highs, while disciplined capital allocation and robust cash flow support ongoing investments and share repurchases.
HealthEquity Earnings release: Q2 2027
HealthEquity released its Q2 2027 earnings on August 27, 2026, summarizing the period's financial results.
HealthEquity Quarterly report: Q2 2027
HealthEquity has published its Q2 2027 quarterly earnings report on August 27, 2026.
HealthEquity backs FY27 adjusted EPS view $4.66-$4.73, consensus $4.72
Raises FY27 revenue view to $1.411B-$1.421B from $1.41B-$1.42B, consensus $1.42B. Raises FY27 adjusted EBITDA view to $628M-$636M from $625M-$633M. The company said, “For the fiscal year ending Januar...
HealthEquity reports Q2 EPS $1.24, consensus $1.19
Reports Q2 revenue $350.73M, consensus $349.23M. “HealthEquity (HQY) delivered a record-setting second quarter, with record Adjusted EBITDA margin of 48%, record HSA accounts of 10.7 million and recor...
HealthEquity Reports Second Quarter Ended July 31, 2026 Financial Results
Highlights of the second quarter include: Net income increased 10% to $65.6 million, and net income margin increased to 19% from 18% last year. Adjusted EBITDA increased 11% to $167.0 million, and Adj...
HealthEquity Announces Second Quarter Earnings Release Date and Investor Conference Schedule
DRAPER, Utah, Aug. 03, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the largest independent health savings account (HSA) custodian by account volume and...
HealthEquity price target raised to $115 from $110 at BTIG
BTIG analyst David Larsen raised the firm’s price target on HealthEquity (HQY) to $115 from $110 and keeps a Buy rating on the shares as part of a broader research…
HealthEquity Transcript: AGM 2026
The meeting established a quorum and approved all proposals, including director elections, auditor ratification, executive compensation, and equity plans. No shareholder questions were submitted, and official voting results will be filed in a Form 8-K.
One in Three Americans Delay Medical Care Due to Cost, HealthEquity Research Finds
Healthcare Cost Pressures Drive Workplace Productivity Losses; HSA Holders Report Stronger Confidence and Control Healthcare Cost Pressures Drive Workplace Productivity Losses; HSA Holders Report Stro...
HealthEquity price target raised to $111 from $110 at Citizens
Citizens raised the firm’s price target on HealthEquity (HQY) to $111 from $110 and keeps an Outperform rating on the shares. HealthEquity posted another “solid” print, issuing “encouraging” pipeline ...
HealthEquity price target raised to $108 from $100 at RBC Capital
RBC Capital analyst Daniel Perlin raised the firm’s price target on HealthEquity (HQY) to $108 from $100 and keeps an Outperform rating on the shares. The company’s Q1 results demonstrate…
HealthEquity price target raised to $125 from $115 at BofA
BofA analyst Allen Lutz raised the firm’s price target on HealthEquity (HQY) to $125 from $115 and keeps a Buy rating on the shares after the company reported a strong…
HealthEquity reports Q1 EPS $1.24, consensus $1.11
Reports Q1 revenue $354.64M, consensus $352.17M. “HealthEquity (HQY) delivered strong first-quarter results, with Adjusted EBITDA margin expanding to 46% and a raised fiscal 2027 outlook,” said Scott ...
HealthEquity raises FY27 EPS view to $4.66-$4.73 from $4.56-$4.65
Consensus $4.63. Backs FY27 revenue view $1.41B-$1.42B, consensus $1.41B. The company said, “For the fiscal year ending January 31, 2027, management expects revenues of $1.410 billion to $1.420 billio...
HealthEquity announces additional $1B of common stock repurchases
In May, the company’s board of directors authorized an additional $1B of common stock repurchases under the program.
HealthEquity Earnings Call Transcript: Q1 2027
Q1 FY27 saw strong revenue and margin growth, driven by robust HSA asset expansion, digital engagement, and AI-enabled efficiencies. Raised full-year guidance and a $1B increase in share repurchase authorization reflect confidence in durable growth.
HealthEquity Earnings release: Q1 2027
HealthEquity released its Q1 2027 earnings on May 28, 2026, summarizing the period's financial results.
HealthEquity Quarterly report: Q1 2027
HealthEquity has published its Q1 2027 quarterly earnings report on May 28, 2026.
HealthEquity Reports First Quarter Ended April 30, 2026 Financial Results; Raises Guidance
Increases Repurchase Program by $1.0 Billion Highlights of the first quarter include: Net income increased 29% to $69.4 million, and net income margin increased to 20% from 16% last year. Adjusted EBI...
HealthEquity Proxy statement: Proxy filing
HealthEquity filed a proxy statement on May 13, 2026, providing details for shareholder voting and corporate governance matters.